Inhibition of T-Cell Proliferation by Anti–HLA Class I MoAbs
| Activator . | Control . | MoAb903-150 . | YTH8623-150 . | W6/323-150 . | TP25.993-150 . | ||||
|---|---|---|---|---|---|---|---|---|---|
| . | [3H]TdR Incorporation (cpm × 10−3) . | [3H]TdR Incorporation (cpm × 10−3) . | Percent Inhibition . | [3H]TdR Incorporation (cpm × 10−3) . | Percent Inhibition . | [3H]TdR Incorporation (cpm × 10−3) . | Percent Inhibition . | [3H]TdR Incorporation (cpm × 10−3) . | Percent Inhibition . |
| Medium | 0.8 ± 0.2 | 0.4 ± 0.3 | — | 0.1 ± 0.1 | — | 0.5 ± 0.2 | — | 0.6 ± 0.3 | — |
| PHA ( 5 μg/mL) | 78.0 ± 6.4 | 31.3 ± 4.0 | 59.9 | 3.0 ± 0.7 | 96.2 | 44.5 ± 8.6 | 43.0 | 40.5 ± 6.1 | 52.0 |
| Con A (10 μg/mL) | 43.5 ± 5.3 | 12.1 ± 1.8 | 72.2 | 0.6 ± 0.2 | 98.6 | 21.6 ± 2.9 | 50.5 | 21.7 ± 3.2 | 50.4 |
| iOKT3 (5 μg/mL) | 70.2 ± 6.8 | 28.8 ± 4.1 | 59.0 | 1.0 ± 0.9 | 98.5 | 30.2 ± 3.5 | 57 | 43.1 ± 4.7 | 38.7 |
| SEB (50 ng/mL) | 28.7 ± 3.5 | 15.3 ± 1.6 | 46.7 | 2.2 ± 0.8 | 92.3 | 14.8 ± 1.3 | 48.3 | 18.5 ± 1.8 | 35.6 |
| PMA (10 ng/mL) | 28.4 ± 4.3 | 10.8 ± 2.7 | 62.0 | 0.6 ± 0.4 | 97.9 | 26.9 ± 5.2 | 5.2 | 29.3 ± 3.1 | 0 |
| PWM (1/300) | 6.1 ± 1.1 | 3.0 ± 0.5 | 50.8 | ND | ND | ND | ND | ND | ND |
| MLR (Raji cells) | 8.2 ± 1.3 | 0.9 ± 0.5 | 89.0 | 0.1 ± 0.1 | 99.1 | 1.4 ± 0.2 | 82.9 | 0.6 ± 0.4 | 92.7 |
| Activator . | Control . | MoAb903-150 . | YTH8623-150 . | W6/323-150 . | TP25.993-150 . | ||||
|---|---|---|---|---|---|---|---|---|---|
| . | [3H]TdR Incorporation (cpm × 10−3) . | [3H]TdR Incorporation (cpm × 10−3) . | Percent Inhibition . | [3H]TdR Incorporation (cpm × 10−3) . | Percent Inhibition . | [3H]TdR Incorporation (cpm × 10−3) . | Percent Inhibition . | [3H]TdR Incorporation (cpm × 10−3) . | Percent Inhibition . |
| Medium | 0.8 ± 0.2 | 0.4 ± 0.3 | — | 0.1 ± 0.1 | — | 0.5 ± 0.2 | — | 0.6 ± 0.3 | — |
| PHA ( 5 μg/mL) | 78.0 ± 6.4 | 31.3 ± 4.0 | 59.9 | 3.0 ± 0.7 | 96.2 | 44.5 ± 8.6 | 43.0 | 40.5 ± 6.1 | 52.0 |
| Con A (10 μg/mL) | 43.5 ± 5.3 | 12.1 ± 1.8 | 72.2 | 0.6 ± 0.2 | 98.6 | 21.6 ± 2.9 | 50.5 | 21.7 ± 3.2 | 50.4 |
| iOKT3 (5 μg/mL) | 70.2 ± 6.8 | 28.8 ± 4.1 | 59.0 | 1.0 ± 0.9 | 98.5 | 30.2 ± 3.5 | 57 | 43.1 ± 4.7 | 38.7 |
| SEB (50 ng/mL) | 28.7 ± 3.5 | 15.3 ± 1.6 | 46.7 | 2.2 ± 0.8 | 92.3 | 14.8 ± 1.3 | 48.3 | 18.5 ± 1.8 | 35.6 |
| PMA (10 ng/mL) | 28.4 ± 4.3 | 10.8 ± 2.7 | 62.0 | 0.6 ± 0.4 | 97.9 | 26.9 ± 5.2 | 5.2 | 29.3 ± 3.1 | 0 |
| PWM (1/300) | 6.1 ± 1.1 | 3.0 ± 0.5 | 50.8 | ND | ND | ND | ND | ND | ND |
| MLR (Raji cells) | 8.2 ± 1.3 | 0.9 ± 0.5 | 89.0 | 0.1 ± 0.1 | 99.1 | 1.4 ± 0.2 | 82.9 | 0.6 ± 0.4 | 92.7 |
Proliferation was assessed by [3H]TdR incorporation during the last 12 hours of 72 or 120 hours of culture in the presence of mitogens or allogeneic cells, respectively. Results are expressed as cpm ± SD and are representative of four separate experiments.
Abbreviation: ND, not determined.
MoAb90, W6/32, TP25.99, and YTH862 at 10 μg/mL and activators were added simultaneously to the cells (2 × 105/well).